Tscan Therapeutics is trading 5.31% up at $0.39 after a modest recovery from the sharp selloff triggered by its September 2, 2026 strategic reorganization announcement.
- Paused Phase 3 ALLOHA-2 enrollment because of insufficient capital.
- Shifted focus toward in vivo solid-tumor therapies and announced approximately 75% workforce reductions.
- Broader markets are trading lower on stronger employment data.